Sotyktu (deucravacitinib) is used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu is a Tyrosine Kinase 2 (TYK2) Inhibitor, which works by binding to the tyrosine kinase 2 protein and preventing the activation of a downstream inflammatory response. Sotyktu is available as a 6mg tablet. There are currently no generic alternatives for Sotyktu. It is covered by some Medicare and insurance plans, but some pharmacy coupons or cash prices may be lower.